Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

(2019) Charles S Fuchs et al.   LANCET ONCOLOGY

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).

(2019) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study

(2018) Kensei Yamaguchi et al.   Gastric Cancer

Gastric cancer: epidemiology, prevention, classification, and treatment

(2018) Robert Sitarz et al.   Cancer Management and Research

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).

(2018) Kei Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).

(2018) Daisuke Takahari et al.   JOURNAL OF CLINICAL ONCOLOGY

NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.

(2018) Michael Cecchini et al.   JOURNAL OF CLINICAL ONCOLOGY

Perspectives of HER2-targeting in gastric and esophageal cancer

(2017) James N Gerson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) E. C. Smyth et al.   ANNALS OF ONCOLOGY

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

(2016) H. H. Yoon et al.   ANNALS OF ONCOLOGY

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

FDA Approval Summary: Ramucirumab for Gastric Cancer

(2015) S. J. Casak et al.   CLINICAL CANCER RESEARCH

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer

(2014) M. Javle et al.   CLINICAL CANCER RESEARCH

Global burden of gastric cancer attributable toHelicobacterpylori

(2014) Martyn Plummer et al.   INTERNATIONAL JOURNAL OF CANCER

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

(2013) Jeffrey Melson Clarke et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY